ADR120S

ADR120S EBIT per Share

The EBIT per Share of ADR120S (3750.T) as of Nov 3, 2026 is -101.50 JPY. In the previous year, EBIT per Share was -90.38 JPY — a change of 12.31% (lower).

EBIT per Share

-101.50JPY

YoY

12.31%

Last updated:

EBIT per Share of ADR120S is 2026 -101.50 JPY. EBIT per Share of ADR120S was 2025 -90.38 JPY. It decreases by 12.31% lower compared to the previous year.

The ADR120S EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
43.50 JPY
Jan 1, 2021
-82.02 JPY
Jan 1, 2022
-51.78 JPY
Jan 1, 2023
-88.97 JPY
Jan 1, 2024
-86.55 JPY
Jan 1, 2025
-90.38 JPY
Jan 1, 2026
-101.50 JPY
Jan 1, 2027 (e)
0.00 JPY
The ADR120S EBIT per Share history
YEAREBIT per ShareYoY
est0.00JPY-100.00%
-101.50JPY+12.31%
-90.38JPY+4.42%
-86.55JPY-2.72%
-88.97JPY+71.82%
-51.78JPY-36.87%
-82.02JPY-288.56%
43.50JPY-11.58%
49.19JPY+138.82%
20.60JPY-134.72%
-59.33JPY+70.02%
-34.90JPY-176.17%
45.82JPY+27.92%
35.82JPY-665.28%
-6.34JPY+112.42%
-2.98JPY+198.80%
-1.00JPY-98.34%
-60.17JPY-1.80%
-61.27JPY+29.93%
-47.16JPY-21,150.00%
0.22JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ADR120S Stock analysis

What does ADR120S do? ADR120S Inc generates revenue through its Real Asset segment, which involves buying and selling real estate, developing and operating hotels, and investing in real estate projects. The Medical segment focuses on regenerative medicine, selling medical equipment like the Celusion centrifuge and Celusion cell therapy kit, and providing cell therapy services. The company serves clients in real estate development, hotel operations, and healthcare sectors, with products targeting medical facilities and clinics specializing in regenerative treatments. The Real Asset segment handles property transactions, hotel management, and real estate investments, while the Medical segment offers cell therapy solutions through its branded products. Both segments target businesses seeking to expand in real estate or adopt advanced medical technologies, with the Celusion products being key revenue drivers in the healthcare market. ADR120S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ADR120S stock

EBIT per Share of ADR120S is -101.50 JPY in 2026.

EBIT per Share of ADR120S changed from -90.38 JPY to -101.50 JPY, representing a 12.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share ADR120S since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ADR120S

All Key Metrics — ADR120S